Aug 18, 2021, 22:45 pm
(This post was last modified: Aug 19, 2021, 03:58 am by Resurgence. Edited 4 times in total.)
Scientists behind the AstraZeneca Covid-19 jab are now making a jab to fight the plague.
The first trial volunteers have been given the new plague vaccine created by UK scientists belonging to the Oxford Vaccine Group.
At least 40 healthy 18- to 55-year-olds will take part in phase one of the trials to test the vaccine.
Using the same technology as the as the coronavirus inoculation, it will be used to target the centuries-old bacterial threat of the bubonic plague.
Infamously known as the Black Death, it swept through much of Europe during the 1300s, wiping out around half the population.
Cases of the plague are still reported in some remote areas of Africa, Asia and America today.
Plague vaccine volunteer Larissa told the BBC she “didn’t hesitate” to take part in the experience.
Asked whether she was worried about possible side-effects from the vaccine, she said:
The vaccine uses a weakened version of the common cold virus, adenovirus, which has been taken from chimpanzees and genetically changed so it cannot cause infection in people.
It does not contain plague bacterium, but instead it uses added genes that make proteins from the bacterium.
This should inform the body’s immune system how to fend off a real infection should it ever need to.
The trial will monitor how well the body recognises and learns to fight the plague after receiving the vaccine.
Plague can be a very severe disease in people, with a case-fatality ratio of 30 per cent to 60 per cent for the bubonic type. It is almost always fatal for the pneumonic kind when left untreated.
However, infection is rare and mainly affects people in remote areas of the world.
According to the World Health Organization (WHO), there are around 1000 to 2000 recorded cases a year, though they believe the true number is likely much higher.
As an animal disease, plague can be found in all continents, except Oceania. There is a risk of human plague wherever the presence of plague natural foci – the bacteria, an animal reservoir and a vector – and human population co-exist.
Currently, the three most endemic countries are the Democratic Republic of the Congo, Madagascar, and Peru.
As of 11 July 2021, from 1 January 2021 to 20 June 2021, a total of 117 suspected cases of bubonic and pulmonary plague and 13 deaths were reported in Ituri province of the Democratic Republic of the Congo.
In 2017, an outbreak killed 171 people in Madagascar.
https://inews.co.uk/news/health/plague-v...ed-1156444
------------------------------------------------------------------------------------------------------------------------------------------------------
It is unusual and also worrying that they would consider a plague vaccine a priority during a COVID-19 pandemic.
They must know something we don't.
The first trial volunteers have been given the new plague vaccine created by UK scientists belonging to the Oxford Vaccine Group.
At least 40 healthy 18- to 55-year-olds will take part in phase one of the trials to test the vaccine.
Using the same technology as the as the coronavirus inoculation, it will be used to target the centuries-old bacterial threat of the bubonic plague.
Infamously known as the Black Death, it swept through much of Europe during the 1300s, wiping out around half the population.
Cases of the plague are still reported in some remote areas of Africa, Asia and America today.
Plague vaccine volunteer Larissa told the BBC she “didn’t hesitate” to take part in the experience.
Quote:“I just wanted to do my bit,” she said.
Asked whether she was worried about possible side-effects from the vaccine, she said:
Quote:“I’m not too concerned.
“The vaccine that’s being assessed today is using the same platform as the Covid vaccine, which has literally been administered to millions of people around the world.”
The vaccine uses a weakened version of the common cold virus, adenovirus, which has been taken from chimpanzees and genetically changed so it cannot cause infection in people.
It does not contain plague bacterium, but instead it uses added genes that make proteins from the bacterium.
This should inform the body’s immune system how to fend off a real infection should it ever need to.
The trial will monitor how well the body recognises and learns to fight the plague after receiving the vaccine.
Plague can be a very severe disease in people, with a case-fatality ratio of 30 per cent to 60 per cent for the bubonic type. It is almost always fatal for the pneumonic kind when left untreated.
However, infection is rare and mainly affects people in remote areas of the world.
According to the World Health Organization (WHO), there are around 1000 to 2000 recorded cases a year, though they believe the true number is likely much higher.
As an animal disease, plague can be found in all continents, except Oceania. There is a risk of human plague wherever the presence of plague natural foci – the bacteria, an animal reservoir and a vector – and human population co-exist.
Currently, the three most endemic countries are the Democratic Republic of the Congo, Madagascar, and Peru.
As of 11 July 2021, from 1 January 2021 to 20 June 2021, a total of 117 suspected cases of bubonic and pulmonary plague and 13 deaths were reported in Ituri province of the Democratic Republic of the Congo.
In 2017, an outbreak killed 171 people in Madagascar.
https://inews.co.uk/news/health/plague-v...ed-1156444
------------------------------------------------------------------------------------------------------------------------------------------------------
It is unusual and also worrying that they would consider a plague vaccine a priority during a COVID-19 pandemic.
They must know something we don't.